Cedars-Sinai Health Ventures

James D. Laur, Managing Director of the venture arm and Chief Intellectual Property Officer at Cedars-Sinai, oversees strategy and deal execution. Maureen Klewicki serves as Partner and Head of Investing, running day-to-day investment activities. Both report through the health system's innovation and IP infrastructure, keeping investment decisions aligned with clinical and operational priorities.

Deal flow originates primarily from Cedars-Sinai's own physicians, researchers, and clinical departments who identify tools they want to use inside the health system. The venture team also evaluates companies through the system's technology-scouting networks, accelerator programming, and convenings like the LSI Emerging Medtech Summit. This internal-referral model means most portfolio companies enter the pipeline because a practicing clinician or IT leader has already flagged the need.

It is neither — Cedars-Sinai Health Ventures functions as a strategic venture arm of a nonprofit academic medical center. The capital comes from the hospital's balance sheet rather than from a family or external LPs. The firm looks like a corporate venture capital unit in practice, though its parent is a nonprofit institution, giving it a hybrid posture between impact-first and return-seeking.

Public record points almost exclusively to direct investments into healthcare companies, often at early to growth stages. There is no disclosed activity around fund-of-funds commitments or LP stakes in external venture funds. The firm's model favors directing capital into companies where Cedars-Sinai can serve as a clinical partner, first customer, or validation site — something indirect fund commitments generally do not permit.

Cedars-Sinai Health Ventures is a wholly owned and integrated division of Cedars-Sinai Medical Center, not a separately capitalized external entity. The venture arm's managing director, James Laur, also serves as the medical center's Chief Intellectual Property Officer. This dual role ensures that investment strategy, technology transfer, and clinical innovation stay bound together under the same organizational roof.

The venture arm itself is not a philanthropic entity, but its parent, Cedars-Sinai Medical Center, is a major nonprofit institution with a large fundraising and grantmaking apparatus. Investment returns cycle back into the medical center's mission, creating an indirect philanthropic linkage. There is no separately disclosed donor-advised fund or private foundation attached directly to the venture vehicle.

The firm has not publicly outlined a formal co-investment program, but its participation in networks like LSI Emerging Medtech Summit and MedtechWOMEN signals openness to syndicate with other healthcare-focused investors. Given the medical center's role as a clinical partner, co-investors often gain indirect access to Cedars-Sinai's validation infrastructure, making the venture arm a sought-after syndicate partner for medtech and digital health deals.